We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
120 hedge funds and large institutions have $343M invested in Entrada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
28% more capital invested
Capital invested by funds: $269M → $343M (+$74.6M)
5% more funds holding
Funds holding: 114 → 120 (+6)
2.62% more ownership
Funds ownership: 68.47% → 71.09% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
120
Holders Change
+6
Holders Change %
+5.26%
% of All Funds
1.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
47
Reduced
32
Closed
13
Calls
$292K
Puts
–
Net Calls
+$292K
Net Calls Change
+$176K
Top Buyers
| 1 |
BlackRock
New York
|
+$2.42M |
| 2 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$2.35M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$2.28M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.28M |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.83M |
Top Sellers
| 1 |
RA
Royce & Associates
New York
|
-$1.45M |
| 2 |
AG
Algert Global
San Francisco,
California
|
-$1.32M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.14M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.01M |
| 5 |
Morgan Stanley
New York
|
-$964K |
